Biotechnology News

RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related...

FDA Fast Track Designation underscores the urgency of developing new treatment options and the potential of SOT106 to address a significant medical need.

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to...

MicrobiotiX completes MP101's sentinel cohort, with no safety concerns preventing continuation of its first-in-human Phase 1 pneumonia trial.

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with...

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained...

Selskabsmeddelelse 21/2026                                                                   26 august 2026                                                               BESTYRELSESMEDLEMMERS,...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing...

WESTFIELD, N. J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- JATT III Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company,...